Session » Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy IV: Biomarkers

Date: Tuesday, November 15, 2016

Time: 4:30PM-6:00PM

Meeting: 2016 ACR/ARHP Annual Meeting

Abstract Number: 3089

Predicting the Response to TNF Inhibition or B Cell Depletion Therapy from Peripheral Whole Blood Gene Expression Profiles in Patients with Rheumatoid Arthritis

Abstract Number: 3090

Inflammation Detected with Modern Sensitive MRI Analysis Demonstrates That Therapeutic Response As Early As One Month Predicts 12-Month Radiographic Progression: Data from a Study Using Tofacitinib and Methotrexate in Early RA

Abstract Number: 3091

Effect of Sarilumab on Circulating Biomarkers of Bone and Joint Destruction in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate

Abstract Number: 3092

Predictive Factors for Better Outcome of Switching of Biologics for Patients with Rheumatoid Arthritis in Daily Clinical Practice

Abstract Number: 3093

Comparison of Changes in Cardiovascular Risk-Associated Biomarkers in RA Patients Treated with Anti-TNF or Other Biological Agents: A Metabolic Study from a Randomized Trial

Abstract Number: 3094

Factors Associated with Initial or Subsequent Choice of Biologic Disease Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis

« View all sessions from this meeting